Aim: Decubitus ulcers are a significant cause of morbidity and mortality, and a source of considerable expense in health expenditures. Bacteremia is a frequently seen complication of decubitus ulcers, although its incidence has yet to be well defined, and there are scarce studies on the subject. The aim in the present study is to assess the frequency of bacteremia of decubitus ulcer origin as an indicator in decisions to start systemic antibiotics in patients with decubitus ulcers. Material and metods: Included in the study were all patients over the age of 18 years receiving palliative care in hospital, and with a decubitus ulcer. All decubitus wounds were washed with sterile saline and a sample was taken using a sterile cotton swab from the deepest and the most solid part of the wounds. we included 76 patients whose 40 (52.6%) were male and 36 (47.4%) were female, with a mean age of 70.8±15.6 (18-95) years. Among the 76 patients, 75 (65.2%) had decubitus ulcer infections at 115 different sites of the body. Result: The rate of bacteremia in decubitus ulcers was 13.9% (16/115) , and the agents were found to be polymicrobial in the wound cultures of 42 (55.2%) of the patients. The most common accompanying bacteria were acinetobacter, Pseudomonas aeruginosa and E.coli. Among the decubitus ulcers, 49 (42.6%), 60 (52.4%) and 6 (5.2%) were evaluated as stage 4, 3 and 2 decubitus ulcers, respectively. Conclusion: The causative agent of decubitus infections was found to be the agent causing bacteremia in 13.9% of the patients with decubitus ulcers in the present study. The agent growing in the wound culture was rarely found to be the causative agent of bacteremia when deciding whether to treat decubitus ulcer infections.

Objective: Frailty among the elderly refers to those with limited daily activity secondary to their physical, mental, psychological and/or social limits, in addition to comorbid diseases. The use of drugs with anticholinergic burden (ACB) may lead to both unexpected adverse effects and an increased risk of frailty. In this study, we evaluated the effect of anticholinergic burden on frail patients admitted to the geriatric outpatient clinic. Materials and Methods: Included in this prospective study were 125 frail patients aged 65 and above who presented to geriatric outpatient clinics between March and November 2016. The Fried Criteria were applied for the diagnosis of frailty in patients, with five clinical properties were assessed individually in each patient. The Anticholinergic Cognitive Burden Scale was used to calculate the anticholinergic burden score for each patient. Results: A total of 125 elderly frail patients were included in the study, with a mean age of 76.746.67 years. The patients were composed of 77 (61.6%) women and 48 (38.4%) men. The effect of ACB was evaluated in the frail patients. In the frail patient group, 71 patients (56.8%) used no drugs with ACB, while 54 patients (43.2%) had a history of using drugs with ACB. Patients in the two frail group were evaluated based on the presence of anticholinergic burden. The mean walking speed was found to be significantly different in the two groups (p<0.001). The weight of the patients in ACB present and none groups were compared with a t-test, and the difference between them was found to be significant (p<0.05), and weight loss was found to be greater in patients with ACB present group. Conclusion: Use of drugs with an anticholinergic burden may be a risk factor for frailty by decreasing walking speed.